Detalhe da pesquisa
1.
Empagliflozin in Patients with Chronic Kidney Disease.
N Engl J Med
; 388(2): 117-127, 2023 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36331190
2.
Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY.
Clin Exp Nephrol
; 2024 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38643286
3.
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
Breast Cancer Res
; 25(1): 67, 2023 06 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37308971
4.
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.
Br J Cancer
; 116(2): 175-185, 2017 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-28006816
5.
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Lancet Oncol
; 17(5): 577-89, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27083334
6.
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
Lancet Oncol
; 16(2): 141-51, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25589191
7.
Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3.
Cancer Sci
; 106(9): 1202-11, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26094656
8.
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Lancet Oncol
; 15(2): 213-22, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24439929
9.
Phase II study of Afatinib as third-line treatment for patients in Korea with stage IIIB/IV non-small cell lung cancer harboring wild-type EGFR.
Oncologist
; 19(7): 702-3, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24868099
10.
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations.
J Clin Oncol
; 41(16): 2869-2876, 2023 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37235976
11.
Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR.
Oncologist
; 20(5): 570, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25956899
12.
Characterization of gut microbiomes of household pets in the United States using a direct-to-consumer approach.
PLoS One
; 15(2): e0227289, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32078625
13.
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.
J Cancer Res Clin Oncol
; 145(6): 1569-1579, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30783814
14.
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6).
Patient
; 11(1): 131-141, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29178024
15.
Visualizing Internet routing changes.
IEEE Trans Vis Comput Graph
; 12(6): 1450-60, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-17073368
16.
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
J Thorac Oncol
; 11(3): 380-90, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26823294
17.
Respimat Soft Mist inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfaction.
Treat Respir Med
; 4(1): 53-61, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-15725050
18.
Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer.
J Thorac Oncol
; 10(4): 665-72, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25514804
19.
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.
Lung Cancer
; 88(1): 63-9, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25682316
20.
Evaluation of the efficacy and safety of tiotropium bromide (5 µg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease.
Chin Med J (Engl)
; 126(19): 3603-7, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24112149